BiotechTube
DynamiCure

DynamiCure

Cambridge, United States· Est.
dynamicure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $56M

Overview

DynamiCure Biotechnology is a clinical-stage biotech co-founded by PD-L1 pioneer Dr. Lieping Chen, translating immuno-normalization insights into novel therapies. Its lead program DC-6001 comprises two anti-CD93 monoclonal antibodies (DCBY02 and DCSZ11) that are in Phase 1 trials for advanced solid tumors, designed to reprogram the tumor microenvironment. With a pipeline targeting oncology and autoimmune diseases, the company aims to deliver first-in-class and best-in-class antibody treatments for patients worldwide.

OncologyAutoimmune diseases

Technology Platform

Antibody-based immuno-normalization targeting the CD93 pathway to normalize tumor vasculature and remodel the tumor microenvironment.

Funding History

1
Total raised:$56M
Series A$56M

Opportunities

DynamiCure’s first-in-class CD93-targeting antibodies offer a novel mechanism to enhance the efficacy of existing immuno-oncology therapies, potentially opening a large market for combination treatments.
The platform could also be applied to autoimmune diseases, broadening its therapeutic impact.

Risk Factors

As an early clinical-stage company, DynamiCure faces significant development and regulatory risks, including the possibility that CD93 blockade may not translate to clinical benefit.
Competition from other vascular normalization approaches and the need for substantial additional funding are also key challenges.

Competitive Landscape

The tumor vasculature normalization field includes agents targeting VEGF and angiopoietin pathways, but no approved therapies specifically target CD93. DynamiCure's distinct epitope-specific antibodies may offer a unique mechanism to reprogram the tumor microenvironment, positioning it as a potential first-in-class therapy complementary to checkpoint inhibitors.

More companies in Biologics / Biosimilars →More companies in United States →